Ranbaxy and EPIRUS to sign licensing agreement

Last Updated : Jan 09 2014 | 11:55 PM IST

For biosimilar product

Ranbaxy Laboratories and EPIRUS Switzerland GmBH have announced the signing of licensing agreement for BOW015, a biosimilar version of Infliximab.

Powered by Capital Market - Live News

Connect with us on WhatsApp

More From This Section

Surana Telecom and Power appoints wholetime director

Surana Ventures appoints director

Kalyani Forge to appoint company secretary

Carborundum Universal to convene board meeting

First Published: Jan 09 2014 | 10:58 AM IST

Explore News

Next Story